Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs - Footnotes (Detail) - USD ($) $ in Millions				3 Months Ended			12 Months Ended
		Oct. 05, 2022	Mar. 11, 2022	Dec. 31, 2023	Dec. 31, 2022	Apr. 03, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]
Restructuring charge (credit)	[1]						$ 1,968	$ 882	$ 741
Seagen [Member] | Restructuring Charges and Acquisition-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Post closing compensation expense				$ 476
Arena [Member] | Restructuring Charges and Acquisition-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Post closing compensation expense			$ 138			$ 138
GBT [Member] | Restructuring Charges and Acquisition-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Post closing compensation expense		$ 136			$ 136
Biopharma [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charge (credit)							672	354	610
Biopharma [Member] | Realigning Our Cost Base Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charge (credit)							665
Restructuring charges incurred to date				665			665
Biopharma [Member] | Transforming to a More Focused Company Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charge (credit)							(20)	$ 291	$ 612
Restructuring charges incurred to date				$ 1,000			$ 1,000

[1] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: $672 million for 2023 (including charges of $665 million for Realigning our Cost Base Program and credits of $20 million for Transforming to a More Focused Company program), $354 million for 2022 (including charges of $291 million for Transforming to a More Focused Company program) and $610 million for 2021 (including charges of $612 million for Transforming to a More Focused Company program).